Sotera Health (NASDAQ:SHC) Updates FY 2026 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.930-1.01 for the period, compared to the consensus estimate of 0.910. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Sotera Health Stock Performance

SHC opened at $17.49 on Tuesday. The business has a 50 day simple moving average of $17.99 and a two-hundred day simple moving average of $16.81. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of 92.06 and a beta of 1.82. The company has a debt-to-equity ratio of 4.04, a current ratio of 2.38 and a quick ratio of 2.18. Sotera Health has a one year low of $9.53 and a one year high of $19.85.

Wall Street Analysts Forecast Growth

SHC has been the subject of a number of research analyst reports. BMO Capital Markets assumed coverage on Sotera Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $19.00 price target for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Sotera Health in a report on Monday, December 29th. Zacks Research cut shares of Sotera Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Barclays lifted their target price on shares of Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Finally, William Blair assumed coverage on shares of Sotera Health in a research note on Thursday, December 18th. They issued an “outperform” rating for the company. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Insiders Place Their Bets

In other Sotera Health news, CEO Michael B. Jr. Petras sold 434,104 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $16.45, for a total transaction of $7,141,010.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gtcr Investment Xi Llc sold 6,480,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total transaction of $105,818,400.00. Following the sale, the director owned 22,735,301 shares in the company, valued at approximately $371,267,465.33. This trade represents a 22.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 17,384,104 shares of company stock worth $284,024,511. 55.12% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sotera Health

A number of hedge funds and other institutional investors have recently bought and sold shares of SHC. Empowered Funds LLC lifted its holdings in shares of Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Sotera Health by 14.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after buying an additional 43,471 shares during the last quarter. Acadian Asset Management LLC increased its position in Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after buying an additional 14,018 shares in the last quarter. Creative Planning raised its stake in Sotera Health by 15.3% during the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after buying an additional 2,673 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Sotera Health by 4.2% during the second quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after buying an additional 12,758 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.